News Focus
News Focus
Post# of 257389
Next 10
Followers 68
Posts 2711
Boards Moderated 0
Alias Born 02/25/2010

Re: bladerunner1717 post# 146349

Tuesday, 07/31/2012 6:24:48 PM

Tuesday, July 31, 2012 6:24:48 PM

Post# of 257389
They said QTc was within FDA thresholds for this issue. You left this bit out

"To further explore the safety and tolerability of ARRY-797, Array is currently conducting a multiple ascending dose trial in healthy volunteers at doses up to 2.5-fold higher than those evaluated in the osteoarthritis pain trial. ARRY-797 has been well-tolerated in this trial to date, and greater QTc prolongations were observed at these higher dose levels. No subject in either trial exhibited an absolute QTc interval >500 msec or a change from baseline >60 msec, two values cited by regulatory authorities, including the FDA, as thresholds of particular concern for cardiac arrhythmia. These QTc observations warrant further evaluation."

Would any BP want to take on this drug?



Unclear to me. I know a couple of p38 are already out there(Roche/BMY/Flexion). Imagine they'd shelve it before even considering a Phase 3.

the 797 drug isnt really in anyone's model, since there were never big hopes for it.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today